Physician profile
John Eldon Hubner
NPI 1861416190
$2,198.88
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $254 · 2021: $199 · 2022: $361 · 2023: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $307.69 | 2019-2023 | Veozah |
| Amgen INC. | $284.28 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $186.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $179.43 | 2019-2023 | |
| Boston Scientific Corporation | $176.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.37 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $152.58 | 2019-2020 | |
| Novo Nordisk INC | $136.38 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $129.64 | 2019-2022 | |
| Abbvie INC. | $80.38 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.02 | 2019-2023 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $64.70 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $56.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.97 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $36.17 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $23.02 | 2022 | |
| Nabriva Therapeutics, Plc | $21.46 | 2022 | |
| Allergan, INC. | $16.15 | 2019 | |
| Amarin Pharma, INC. | $15.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.87 | 2019 | |
| Pfizer INC. | $14.00 | 2019 | |
| Merck Sharp & Dohme LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hubner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.